Methylation-associated silencing of SFRP1 in renal cell carcinoma

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1257-1263

  Awakura, Yasuo ^a   Nakamura, Eijiro ^a   Ito, Noriyuki ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA methylation; Renal cell carcinoma; Secreted frizzled related protein 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA CATENIN; SECRETED FRIZZLED RELATED PROTEIN 1; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; WNT PROTEIN; MEMBRANE PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHROMOSOME 8P; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE LOCATION; GENE LOCUS; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; DNA METHYLATION; GENETICS; KIDNEY TUMOR; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 58149354782     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000138     Document Type: Article

References (27)

1. Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA and van Kessel AG: Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11: 2489-2498, 2002.
2. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, Kawakami S, Baba M, Nakaigawa N, Nagashima Y, Nakatani Y and Hosaka M: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34: 58-68, 2002.
3. Schullerus D, von Knobloch R, Chudek J, Herbers J and Kovacs G: Microsatellite analysis reveals deletion of a large region at chromosome 8p in conventional renal cell carcinoma. Int J Cancer 80: 22-24, 1999.
4. Hatano N, Nishikawa NS, McElgunn C, Sarkar S, Ozawa K, Shibanaka Y, Nakajima M, Gohiji K and Kiyama R: A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library. Mol Carcinog 31: 161-170, 2001.
5. Yamaguchi S, Yoshihiro S, Matsuyama H, Nagao K, Fukunaga K, Matsumoto H, Matsuda K, Oba K and Naito K: The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. Clin Genet 63: 184-191, 2003.
6. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM and Morton DG: The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64: 883-888, 2004.
7. Higgins JP, Wang L, Kambham N, Montgomery K, Mason V, Vogelmann SU, Lemley KV, Brown PO, Brooks JD and van de Rijn M: Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol Biol Cell 15: 649-656, 2004.
8. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36: 417-422, 2004.
9. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149, 2002.
10. Fukui T, Kondo M, Ito G, Maeda O, Sato N, Yoshioka H, Yokoi K, Ueda Y, Shimokata K and Sekido Y: Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24: 6323-6327, 2005.
11. Takada T, Yagi Y, Maekita T, Imura M, Nakagawa S, Tsao SW, Miyamoto K, Yoshino O, Yasugi T, Taketani Y and Ushijima T: Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 95: 741-744, 2004.
12. Sobin L and Wittekind CH: International Union Against Cancer (UICC). In: TNM Classification of Malignant Tumours, 6th edition, Wiley-Liss, New York, 2002.
13. Goldstein NS: Grading of renal cell carcinoma. Urol Clin North Am 26: 637-642, 1999.
14. Hoehn W and Schroeder FH: Renal cell carcinoma: two new cell lines and a serially transplantable nude mouse tumor (NC 65). Preliminary report. Invest Urol 16: 106-112, 1978.
15. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R and Vidaud M: Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59: 2759-2765, 1999.
16. Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y and Yoshida O: HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res 57: 742-746, 1997.
17. Tomlinson IP, Lambros MB and Roylance RR: Loss of heterozygosity analysis: practically and conceptually flawed? Genes Chromosomes Cancer 34: 349-353, 2002.
18. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M and Dahiya R: Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 12: 6989-6997, 2006.
19. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, Knuchel R, Klopocki E, Sauter G, Simon R, Wieland WF, Walter B, Denzinger S, Hartmann A and Hammerschmied CG: Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26: 5680-5691, 2007.
20. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG and Copland JA: Secreted frizzledrelated protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749, 2007.
21. Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, Matsukura S, Matsuo S, Joh K and Mukai T: The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem (Tokyo) 137: 431-440, 2005.
22. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M and Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 22: 847-852, 2003.
23. Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K and Tomita Y: Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of betacatenin gene mutations. Clin Cancer Res 6: 460-466, 2000.
24. Zhu X, Kanai Y, Saito A, Kondo Y and Hirohashi S: Aberrant expression of beta-catenin and mutation of exon 3 of the betacatenin gene in renal and urothelial carcinomas. Pathol Int 50: 945-952, 2000.
25. Oya M, Mikami S, Mizuno R, Marumo K, Mukai M and Murai M: C-jun activation in acquired cystic kidney disease and renal cell carcinoma. J Urol 174: 726-730, 2005.
26. Yun MS, Kim SE, Jeon SH, Lee JS and Choi KY: Both ERK and Wnt/ beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 118: 313-322, 2005.
27. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M and Yoshida O: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187, 1995.